Get the Stockscreener App
23.65
1.50%
-0.36
Elanco Animal Health Inc stock is traded at $23.65, with a volume of 8.28M.
It is down -1.50% in the last 24 hours and up +0.21% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
See More
Previous Close:
$24.01
Open:
$24.16
24h Volume:
8.28M
Relative Volume:
1.57
Market Cap:
$11.81B
Revenue:
$4.72B
Net Income/Loss:
$-232.00M
P/E Ratio:
-50.72
EPS:
-0.4663
Net Cash Flow:
$284.00M
1W Performance:
+5.06%
1M Performance:
+0.21%
6M Performance:
+10.05%
1Y Performance:
+92.59%
1-Day Range:
$22.91
$24.58
1-Week Range:
$22.41
$26.29
52-Week Range:
$11.92
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
23.65 | 11.81B | 4.72B | -232.00M | 284.00M | -0.4663 |
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.11 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
82.83 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
564.94 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
ELAN SEC FilingsElanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan
Elanco Animal Health Price Target Raised to $31.00/Share From $30.00 by Citigroup - Moomoo
ELAN Maintained by Citigroup -- Price Target Raised to $31.00 - GuruFocus
ELAN Maintained by JP Morgan -- Price Target Raised to $30 - GuruFocus
Elanco Earnings Call Highlights Innovation-Led Growth - The Globe and Mail
Elanco Animal Health Is Maintained at Overweight by JP Morgan - Moomoo
Elanco Animal Health Boosts Full Year Forecast - marketscreener.com
Elanco Animal Health (ELAN) Is Up 20.1% After Raising 2026 Guidance On Innovation-Led Growth - Yahoo Finance
Q1 2026 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2026 Earnings Call Transcript - Insider Monkey
Jefferies raises Elanco Animal Health stock price target to $30 By Investing.com - Investing.com Canada
Stifel reiterates Buy on Elanco Animal Health stock, $32 target By Investing.com - Investing.com Canada
ELAN Q1 Deep Dive: Innovation Products and Margin Expansion Steer Strong Start - The Globe and Mail
MSN Money - MSN
Elanco jumps after Q1 beat and higher 2026 outlook - Quiver Quantitative
Elanco Animal Health CEO reveals efforts to stop screwworm outbreak - Fox Business
BofA raises Elanco Animal Health stock price target on strong Q1 - Investing.com Canada
Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum - Benzinga
Elanco Animal Health 2026 Q1 10-Q: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Elanco Animal Health Q1 2026 Earnings Call Transcript - MarketBeat
Elanco’s stock climbs after company posts strong 1st quarter results - Indianapolis Business Journal
Elanco Is Finally Realizing Its Transformation From Caterpillar to Butterfly - Morningstar
Elanco Animal Health Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Elanco (ELAN) Q1 2026 Earnings Transcript - The Globe and Mail
Elanco Animal Health Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Elanco Q1 2026 slides: innovation drives beat, guidance raised - Investing.com
Earnings call transcript: Elanco Animal Health Q1 2026 surpasses expectations with strong growth - Investing.com
elan-20260331 - SEC.gov
Elanco Animal Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Elanco Animal Health Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Elanco (NYSE: ELAN) grows Q1 2026 revenue 15% while profit declines - Stock Titan
Elanco Animal Health Incorporated : Investor Overview - marketscreener.com
Elanco (ELAN) shares climb after strong quarterly results and higher full-year outlook - Yahoo Finance
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Elanco Animal Health Q1 Adjusted Earnings, Revenue Rises; Lifts 2026 Outlook - marketscreener.com
Elanco Animal Health (NYSE:ELAN) Soars After Strong Q1 Beat, Raises Full-Year Outlook - ChartMill
(ELAN) Elanco Animal Health Expects 2026 Revenue Range $5.01B to $5.09B, vs. FactSet Est of $5.00B - marketscreener.com
Earnings Flash (ELAN) Elanco Animal Health Incorporated Posts Q1 Adjusted EPS $0.40 per Share, vs. FactSet Est of $0.35 - marketscreener.com
Elanco stock rises 6% on strong quarter, raised guidance By Investing.com - Investing.com Canada
Global Animal Euthanasia Market to Reach $3.26 Billion by 2036, - openPR.com
Elanco’s (NYSE:ELAN) Q1 CY2026 Sales Beat Estimates - TradingView
GUIDANCE: (ELAN) Elanco Animal Health Expects 2026 Adjusted EPS Range $1.03 to $1.09, Vs. FactSet Est of $1.03 - Moomoo
Elanco Animal Health Reports First Quarter 2026 Results - marketscreener.com
Press Release: Elanco Animal Health Reports First Quarter 2026 Results - Moomoo
Pet Parasite Prevention and Control Market Size Accelerating - openPR.com
ELAN Forecast, Price Target & Analyst Ratings | ELANCO ANIMAL HEALTH INC (NYSE:ELAN) - ChartMill
Elanco (ELAN) officer awarded 65 deferred stock units under plan - Stock Titan
Elanco (NYSE: ELAN) CEO receives grant of deferred stock units as pay - Stock Titan
Elanco (ELAN) CFO receives new deferred stock unit award - Stock Titan
Elanco Animal Health earnings up next: Can innovation offset Pet Health pressure? - Investing.com Canada
Elanco (ELAN) Q1 Earnings: What To Expect - The Globe and Mail
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):